Trajan Group Holdings Ltd (AU:TRJ)
ASX:TRJ
Want to see AU:TRJ full AI Analyst Report?
TRJ Stock Chart & Stats
AU$0.39
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.39
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.97
Previous CloseN/A
Volume3.68K
Average Volume (3M)21.61K
Market Cap
AU$64.09M
Enterprise ValueAU$112.28M
Total Cash (Recent Filing)AU$12.78M
Total Debt (Recent Filing)AU$69.37M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding152,593,050
10 Day Avg. Volume15,523
30 Day Avg. Volume21,606
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.03
Price to Sales (P/S)0.65
P/FCF Ratio16.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.03Price Target Upside162.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$171.27M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueTrajan's business relies on recurring consumables sales, producing predictable repeat revenue from routine lab workflows. This durable revenue stream supports steady demand, customer stickiness, and unit-level economics that help stabilize topline and operational planning over multiple quarters.
Diversified End MarketsServing a broad set of analytical markets (pharma/biopharma, clinical/forensic, environmental, food) reduces exposure to any single cyclical end market. Structural regulatory and R&D trends across these industries create durable demand for lab consumables and instrumentation over the medium term.
Relatively Stable Balance SheetA moderate debt profile and stable equity ratio provide financial flexibility to fund operations and selective investments without excessive leverage. This foundational balance sheet strength supports resilience through product investment cycles and reduces refinancing risk over the next several quarters.
Bears Say
Sustained Net LossesPersistent net losses and a negative net margin undermine retained earnings and limit the company's ability to self-fund growth or absorb shocks. Continued losses constrain reinvestment in R&D and commercial expansion, and may force external financing that dilutes shareholders or raises leverage.
Declining Free Cash FlowA 20% fall in free cash flow weakens the firm's capacity to finance capex, inventory, or strategic initiatives internally. Even with positive operating cash flow coverage, declining FCF reduces margin for error, increases reliance on external funding, and limits flexibility for medium-term growth investments.
Weak Operational MarginsLow operating margins signal cost structure or efficiency issues that limit profit conversion as revenue scales. This reduces resilience to input cost inflation or pricing pressure, constrains cash generation potential, and hampers the company’s ability to reinvest in automation or new product development.
Trajan Group Holdings Ltd News
TRJ FAQ
What was Trajan Group Holdings Ltd’s price range in the past 12 months?
Trajan Group Holdings Ltd lowest share price was AU$0.36 and its highest was AU$0.97 in the past 12 months.
What is Trajan Group Holdings Ltd’s market cap?
Trajan Group Holdings Ltd’s market cap is AU$64.09M.
When is Trajan Group Holdings Ltd’s upcoming earnings report date?
Trajan Group Holdings Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 119 days.
How were Trajan Group Holdings Ltd’s earnings last quarter?
Trajan Group Holdings Ltd released its earnings results on Feb 25, 2026. The company reported AU$0.005 earnings per share for the quarter, beating the consensus estimate of -AU$0.004 by AU$0.009.
Is Trajan Group Holdings Ltd overvalued?
According to Wall Street analysts Trajan Group Holdings Ltd’s price is currently Undervalued.
Does Trajan Group Holdings Ltd pay dividends?
Trajan Group Holdings Ltd does not currently pay dividends.
What is Trajan Group Holdings Ltd’s EPS estimate?
Trajan Group Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trajan Group Holdings Ltd have?
Trajan Group Holdings Ltd has 152,593,050 shares outstanding.
What happened to Trajan Group Holdings Ltd’s price movement after its last earnings report?
Trajan Group Holdings Ltd reported an EPS of AU$0.005 in its last earnings report, beating expectations of -AU$0.004. Following the earnings report the stock price went down -5.042%.
Which hedge fund is a major shareholder of Trajan Group Holdings Ltd?
Currently, no hedge funds are holding shares in AU:TRJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trajan Group Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.03 (162.82% Upside)
AU$1.03 (162.82% Upside)
Insider Transactions
Bought Shares
Worth AU$7.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.50%
12-Months-Change
Fundamentals
Return on Equity
-1.32%
Trailing 12-Months
Asset Growth
-3.37%
Trailing 12-Months
Company Description
Trajan Group Holdings Ltd
Trajan Group Holdings Limited develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company operates through two segments, Analytical Products and Life Science Solutions. It offers analytical products, including syringes, GC consumables, septas, caps, liners, gas filters, and tubing products; pathology solutions; and sampling products, as well as automation systems for the analysis of biological, food, and environmental samples. The company also provides nutrition testing solutions for pathology laboratories, research and clinical trials, personalized nutrition, corporate wellness, and health insurance. In addition, it offers automation workflow solutions, micro sampling devices, and data analysis services. Trajan Group Holdings Limited was incorporated in 2011 and is headquartered in Ringwood, Australia.
TRJ Stock 12 Month Forecast
Average Price Target
AU$1.03
▲(162.82% Upside)
Technical Analysis
Austco Healthcare Limited
―
Cyclopharm Limited
―
Singular Health Group Ltd
―
EZZ Life Science Holdings Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---